SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's earnings have sparked intense debate, with a revenue beat overshadowed by an EPS miss, triggering volatility. The community is focused on the upcoming conference call with Elon Musk, anticipating insights on robotaxis and AI. Broader discussions revolve around Tesla's valuation and future growth prospects in the evolving EV market.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors discuss the implications of the company shipping B1 samples of its QSE-5 cell and active engagements with a new top 10 major OEM. The community is focused on potential partnerships and the company's cash runway extending to 2030 following earnings. Despite some skepticism and debate around valuation, many express confidence in QuantumScape's technology and long-term potential in the battery market.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its community rallies around the idea of 'OG memes' making a comeback, emphasizing community building and a rejection of traditional 'coining'. The community is expressing strong conviction, with many calling for moonshot listings and celebrating its current trending status. Talk centers around the idea that while markets may be uncertain, the 'rage' will continue.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as investors discuss the recent earnings call, pipeline progress, and cash runway, with some expressing concerns about cash burn while others highlight the potential for partnerships and buyout opportunities. The community is weighing the company's prospects in the competitive GLP-1 market against its financial health and the CEO's strategy. Discussions also involve technical analysis, short positions, and potential catalysts for stock movement.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to its quantum computing breakthrough with HSBC, demonstrating improved bond trading predictions and reinforcing IBM's leadership in the sector; this has sparked significant community discussion around its potential impact and commercial applications with many highlighting the potential for IBM to outperform pure-play quantum stocks. Broader context includes positive sentiment around IBM's strategic focus on AI, hybrid cloud, and consulting services, as well as speculation regarding FAA contract and growing partnerships that are creating a buying opportunity.

Molina Healthcare, Inc. engages in the provision of health care services. It operates through the following segments: Medicaid, Medicare, Marketplace, and Other. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.

Molina Healthcare Inc

MOH is trending due to a significant earnings miss, sparking concerns about rising medical costs and the impact of Medicaid trends across the healthcare sector. Community members are discussing potential support levels and comparing MOH to competitors like CNC and UNH, while also speculating on potential catalysts like ACA subsidy extensions. The broader context involves uncertainty around government healthcare policy and its effect on managed care organizations.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group ($UNH) is trending amidst mixed sentiment following competitor earnings and broader sector concerns. Community discussions revolve around margin pressures, potential impacts from government policies, and speculation on upcoming earnings. Some traders anticipate a pre-earnings rally while others remain cautious, citing regulatory scrutiny and economic uncertainty.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is trending amid discussions about earnings, with some celebrating a significant beat while others express concerns about tariffs and broader market conditions. The community is focused on whether the stock's upward momentum can be sustained. Bullish sentiment seems to be building around the company's potential in AI and memory markets.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp. is trending as investors react to sector-wide pressures, particularly following Molina's earnings miss, which has sparked concerns about Medicaid margins and dragged down other healthcare stocks. The community is actively debating whether the dip represents a buying opportunity ahead of Centene's upcoming earnings, with some highlighting its undervalued status and potential for a V-shaped recovery contingent upon ACA subsidy extensions and positive earnings.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Armata Pharmaceuticals is trending due to positive Phase 2a trial results for its AP-SA02 drug, showing promise in treating Staphylococcus aureus bacteremia; the community is excited about the potential for advancement into Phase 3 and the drug's efficacy against antibiotic-resistant strains. Some traders are pointing to the low float and a partnership with Gilead as reasons to be bullish, while others caution about potential dilution and the company's cash runway.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tempus to Report Third Quarter 2025 Financial Results on November 4

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The...

Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy?

TEM's 48% surge, key FDA clearances and bold AI acquisitions set the stage for its Q3 earnings reveal.

Tempus AI Fuels Growth Through Strategic Biotech Collaborations

TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.

Healthtech company Tempus AI (TEM) announced a multi-year collaboration with Whitehawk Therapeutics (WHWK) on Thursday, aimed at developing the latter’s cancer treatment pipeline.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tempus.com/news/pr/tempus-announces-collaboration-with-whitehawk-therapeutics-to-advance-biomarker-driven-oncology-research/">deal</a>, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including a de-identified multimodal database, to support its clinical trial designs. A de-identified multimodal database is a collection of diverse datasets, such as medical images, clinical notes, and genetic information, from which all personally identifiable information or protected health information has been removed. It is expected that Tempus’ dataset will help Whitehawk focus on the right patient population.Whitehawk’s antibody drug conjugate portfolio includes three assets designed to target proteins that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers. The collaboration is aimed at advancing research centered on these candidates.“By partnering with Tempus, our goal is to better understand the expression of our ADC protein targets to inform indication prioritization for our clinical development programs and better exploit the full potential of our pipeline,” said Whitehawk CEO Dave Lennon.<a href="https://stocktwits.com/symbol/WHWK">Whitehawk shares</a> soared 23% on Thursday afternoon at the time of writing, while <a href="https://stocktwits.com/symbol/TEM">Tempus shares</a> dropped about 0.5%.On Stocktwits, retail sentiment around WHWK jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:590/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_12_26_39_PM_png_87d1a96f13.webp" alt="WHWK's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="590" height="61"><figcaption>WHWK's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure>Retail sentiment around TEM, however, stayed within the ‘bearish’ territory, accompanied by ‘low’ message volume.<figure class="image"><img style="aspect-ratio:591/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_12_29_47_PM_png_cc45006531.webp" alt="TEM's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="591" height="61"><figcaption>TEM's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user hopes WHWK rallies into the $4 to $5 range.<stembedurl>https://stocktwits.com/cjstocksup/message/632578934</stembedurl>Another sounded optimistic for TEM stock, citing its relationships with big pharma and strong backlog.<stembedurl>https://stocktwits.com/TICKERTUTOR/message/632569480</stembedurl>WHWK stock has dropped 18% this year, while TEM shares rose 171% during the period.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-stock-rises-after-launch-of-generic-cholestrol-lowering-drug-by-canadian-unit/ch6p4DqR3nu">Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Whitehawk Therapeutics Stock Rallies 25% On Tempus AI Collaboration Deal: Retail Hopes For A Rally Toward $5 Mark

Under the deal, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including, de-identified multimodal database, to support its clinical trial designs.

Equity

Under the deal, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including, de-identified multimodal database, to support its clinical trial designs.


Hims & Hers Elevates Technology-Driven Healthcare Accessibility

HIMS boosts AI-led care with new technology chief, hormone therapies and a global push via its ZAVA acquisition.

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ...

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European...

NVDA & PLTR Driving AI in Health: Top Health IT Stocks for Q3 Earnings

NVDA and PLTR drive AI integration across healthcare, fueling optimism for Omnicell and Tempus AI's Q3 performance.

TEM Expands Partnership With Northwestern Medicine Amid AI Boom

Tempus AI deepens its collaboration with Northwestern Medicine, embedding its AI co-pilot David directly into the health system's EHR to boost clinical efficiency.

Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?

Tempus AI sharpens its edge in precision medicine with key acquisitions, strong R&D launches, and improving financials amid rising competition.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Current Price	$85.27
Prev Close	$89.10
Open	$90.60
Dividend Yield	0.00%
50-Day Moving Average	$83.08
Beta	0.00
Avg. Volume	9M
PE Ratio	-75.23

52-Week High	$104.32
52-Week Low	$31.36
Market Capitalization	$15.48B
EPS (Annual)	-$4.60
Price to Book	49.97
Revenue Per Employee	$288,915.83
Enterprise Value/EBITDA	N/A

TEM
Tempus AI Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TEM News

TEMTempus AI Inc